Zenas Biopharma Inc (ZBIO)

NASDAQ
Currency in USD
11.01
+0.54(+5.16%)
Closed·
After Hours
11.010.00(0.00%)
·
ZBIO Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
ZBIO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
10.1611.26
52 wk Range
5.8326.25
Key Statistics
Edit
Prev. Close
11.01
Open
10.45
Day's Range
10.16-11.26
52 wk Range
5.83-26.25
Volume
82.64K
Average Volume (3m)
179.56K
1-Year Change
-
Book Value / Share
6.8
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ZBIO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
32.14
Upside
+191.94%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year
No news in this category
Looks like there are no results in this news category

Zenas Biopharma Inc Company Profile

Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Compare ZBIO to Peers and Sector

Metrics to compare
ZBIO
Peers
Sector
Relationship
P/E Ratio
−2.8x−0.6x−0.5x
PEG Ratio
−0.040.000.00
Price/Book
1.6x1.8x2.6x
Price / LTM Sales
30.7x10.5x3.0x
Upside (Analyst Target)
217.9%55.8%54.7%
Fair Value Upside
Unlock−2.0%8.4%Unlock

Analyst Ratings

7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 32.14
(+191.94% Upside)

Earnings

Latest Release
May 15, 2025
EPS / Forecast
-0.80 / --
Revenue / Forecast
10.00M / --
EPS Revisions
Last 90 days

FAQ

What Is the Zenas Biopharma (ZBIO) Stock Price Today?

The Zenas Biopharma stock price today is 11.01

What Stock Exchange Does Zenas Biopharma Trade On?

Zenas Biopharma is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Zenas Biopharma?

The stock symbol for Zenas Biopharma is "ZBIO."

What Is the Zenas Biopharma Market Cap?

As of today, Zenas Biopharma market cap is 460.59M.

What Is Zenas Biopharma's Earnings Per Share (TTM)?

The Zenas Biopharma EPS (TTM) is -7.00.

From a Technical Analysis Perspective, Is ZBIO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.